NBY NOVABAY PHARMACEUTICALS INC Disposals and divestitures 8-K Filing 2024 - Asset Sale Update NovaBay Pharmaceuticals is considering terminating an asset sale agreement for its Avenova brand eyecare products after receiving a superior unsolicited offer of $11.5 million from Refresh Acquisitions, compared to the previous offer of $9.5 million from PRN Physician Recommended Nutriceuticals.Get access to all SEC 8-K filings of the NOVABAY PHARMACEUTICALS INC